PHS
ESPR

Pekin Hardy Strauss’s Esperion Therapeutics ESPR Stock Holding History

Pekin Hardy Strauss’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,500
Closed -$23.9K – 367
2024
Q3 		$23.9K Hold
14,500
– – ﹤0.01% 340
2024
Q2 		$32.2K Hold
14,500
– – ﹤0.01% 323
2024
Q1 		$38.9K Hold
14,500
– – 0.01% 322
2023
Q4 		$43.4K Hold
14,500
– – 0.01% 299
2023
Q3 		$14.2K Hold
14,500
– – ﹤0.01% 312
2023
Q2 		$20.2K Hold
14,500
– – ﹤0.01% 311
2023
Q1 		$23.1K Buy
+14,500
New +$74.8K ﹤0.01% 312

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pekin Hardy Strauss's ESPR Position: Q4 2024 in Review

Pekin Hardy Strauss sold out of Esperion Therapeutics (ESPR) in Q4 2024, closing a stake of 14,500 shares — an estimated $23.9K sold.

Pekin Hardy Strauss first reported a position in ESPR in Q1 2023 and held it in 7 quarters. The position peaked at $43.4K in Q4 2023. 189 funds tracked by Wall St. Rank hold ESPR as of Q4 2024.

  • Pekin Hardy Strauss reported no remaining Esperion Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Pekin Hardy Strauss sold 14,500 Esperion Therapeutics shares in Q4 2024, an estimated $23.9K.
  • Pekin Hardy Strauss first reported a position in Esperion Therapeutics in Q1 2023 and held it in 7 quarters.
  • Pekin Hardy Strauss's Esperion Therapeutics position peaked at $43.4K in Q4 2023.
  • 189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2024.

Based on Pekin Hardy Strauss's 13F filing for Q4 2024, filed 4 Feb 2025.